CGRP, PD-1 and PD-L1 as Biomarkers for PICC-Related Bloodstream Infections in Breast Cancer Patients

CGRP, PD-1 and PD-L1 as Biomarkers for PICC-Related Bloodstream Infections in Breast Cancer Patients

Introduction Peripherally inserted central catheter (PICC)-related bloodstream infections (BSIs) are severe complications in breast cancer patients undergoing chemotherapy. This study evaluated the diagnostic potential of calcitonin gene-related peptide (CGRP), programmed cell death protein-1 (PD-1)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun-Tao Tan MD, Lili Hu MD, Qi-Hua Jiang MD, Hai Hu MD, Zhi Yang MD, Zhi-Hua Li PhD, Ping-Hua Hu MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Technology in Cancer Research & Treatment
Online Access:	https://doi.org/10.1177/15330338251342877
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy
by: Bo-Ya Li, et al.
Published: (2025-05-01)

Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01)

Expanding the PD-L1 Paradigm: A Comprehensive Systematic Review and Meta-Analysis of Scoring Systems and Additional Biomarkers Influencing Immune Checkpoint Inhibitor Outcomes in Breast Cancer
by: Shuangwei Mo MBBS, et al.
Published: (2024-10-01)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
by: Di Lu, et al.
Published: (2019-01-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Advances in PD-1 and PD-L1 inhibitors targeted therapies for NSCLC: Mechanisms, Biomarkers, Combination Therapies
by: Xiang Zhiyuan
Published: (2025-01-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
by: Weiming Zhang, et al.
Published: (2024-12-01)

Expression and its clinical significance of sPD-1 and sPD-L1 in patients with primary nephrotic syndrome
by: LV Zhi-an, et al.
Published: (2020-01-01)

Inhibiting ADORA1 enhances glioma apoptosis and increases its sensitivity to anti-PD1 therapy
by: Hong-jiang Li, et al.
Published: (2025-05-01)

Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene
by: Qingqing Jiao, et al.
Published: (2014-01-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer
by: Hao Wang, et al.
Published: (2025-08-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
by: Yi Peng MD, et al.
Published: (2025-01-01)

Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer
by: Xin Li, et al.
Published: (2025-06-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

The PD-1/PD-L1 pathway and Epstein–Barr virus
by: Hui Wang, et al.
Published: (2025-06-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
by: Megan Schollenberger, et al.
Published: (2017-08-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype
by: Muni Hu, et al.
Published: (2025-05-01)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
by: Razelle Kurzrock, et al.
Published: (2020-05-01)

Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
by: Yanling Wang, et al.
Published: (2025-04-01)

DIEP Flap Weights in Immediate 1-stage and 2-stage Breast Reconstruction: Considering Chest Wall Deformity
by: Mariko Inoue, MD, et al.
Published: (2024-12-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

PD-L1 in Breast Cancers and its Prognostic Significance
by: Sayher Kazmi, et al.
Published: (2021-01-01)

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis
by: Jiaojiao Yu, et al.
Published: (2025-05-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

The role of PD-1/PD-L1 in overshooting osteoclastogenesis in periprosthetic joint infections
by: Yi Ren, et al.
Published: (2025-05-01)

In silico identification of promising PD-L1 inhibitors from selected indian medicinal plants for treatment of triple negative breast cancer
by: Sk. Faisal Ahmed, et al.
Published: (2025-01-01)

In silico identification of promising PD-L1 inhibitors from selected indian medicinal plants for treatment of triple negative breast cancer.
by: Sk Faisal Ahmed, et al.
Published: (2025-01-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

Bisecting GlcNAc enhances CD8+ T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1
by: Xueting Ren, et al.
Published: (2025-08-01)

The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer
by: Hao Luo, et al.
Published: (2024-12-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)